Atea Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Atea Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Massachusetts
- Headquarters city
- Boston
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- AVIR
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001593899
- EIN
- 46-0574869
Board of directors
-
Arthur S. Kirsch · DirectorSince 2025
-
Barbara Gayle Duncan · DirectorSince 2023
-
Bruce Polsky · DirectorSince 2023
-
Bruno Lucidi · DirectorSince 2023
-
Franklin M. Berger · DirectorSince 2023
-
Howard Berman · DirectorSince 2025
-
Jean-Pierre Sommadossi · Director · President, CEO, and ChairmanSince 2023
-
Jerome M. Adams · DirectorSince 2023
-
Polly A. Murphy · DirectorSince 2023
Chief executives
Jean-Pierre Sommadossi
· President, CEO, and Chairman
Dates unknown
Director election results
Annual meeting of June 18, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
85.6%
-
87.1%
Board connections
4 of this board's directors also sit on 6 other boards.
- via Polly A. Murphy
- via Howard Berman
- via Arthur S. Kirsch
- via Barbara Gayle Duncan
- via Arthur S. Kirsch
- via Barbara Gayle Duncan
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 18, 2026 | Bruno Lucidi Director | Option exercise | +29,600 | — | — |
| Jun 18, 2026 | Franklin M. Berger Director | Option exercise | +29,600 | — | — |
| Jun 18, 2026 | Barbara Gayle Duncan Director | Option exercise | +29,600 | — | — |
| Jun 18, 2026 | Jerome M. Adams Director | Option exercise | +29,600 | — | — |
| Jun 18, 2026 | Bruce Polsky Director | Option exercise | +29,600 | — | — |
| Jun 18, 2026 | Polly A. Murphy Director | Option exercise | +29,600 | — | — |
| Mar 11, 2026 | Corcoran Andrea Officer (See Remarks) | Option exercise | +60,000 | $1.24 | $74,400 |
| Feb 3, 2026 | Jean-Pierre Sommadossi Director, Officer (President, CEO, and Chairman) | Option exercise | +300,000 | $1.24 | $372,000 |
| Jan 31, 2026 | Horga Maria Arantxa Officer (Chief Medical Officer) | Option exercise | +51,283 | — | — |
| Jan 31, 2026 | Vavricka John Officer (Chief Commercial Officer) | Option exercise | +42,083 | — | — |
| Jan 31, 2026 | Hammond Janet MJ Officer (Chief Development Officer) | Option exercise | +58,050 | — | — |
| Jan 31, 2026 | Corcoran Andrea Officer (See Remarks) | Option exercise | +54,866 | — | — |
| Jan 31, 2026 | Jean-Pierre Sommadossi Director, Officer (President, CEO, and Chairman) | Option exercise | +272,983 | — | — |
| Jan 31, 2026 | Foster Wayne Officer (EVP, Chief Accounting Officer) | Option exercise | +41,333 | — | — |
| Jan 31, 2026 | Horga Maria Arantxa Officer (Chief Medical Officer) | Shares withheld for tax | −16,073 | $4.24 | $68,150 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.